RNU6-351P

Across TCGA pan-cancer cohorts, RNU6-351P RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated RNU6-351P data layer.

The strongest signal is observed in thymoma (THYM), where higher RNU6-351P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-351P expression acts as an unfavorable survival marker.

THYM, STAD, and SARC are the cancer types where RNU6-351P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	DFS	Tertile	II,III,IV	0.145	0.873	<.001	36	view →
STAD	DFS	Tertile	All	0.191	0.595	.006	18	view →
SARC	OS	Tertile	All	0.176	0.860	<.001	18	view →
BLCA	OS	Tertile	All	0.249	0.709	.042	18	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RNU6-351P–THYM (DFS)

Open the THYM breakdown →